Goldman Sachs Remains Neutral on ARIAD Pharmaceuticals (ARIA)
Tweet Send to a Friend
Goldman Sachs maintained a Neutral rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a price target of $3.00. Comments follow Q3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
